[HTML][HTML] Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer
SB Ryoo, S Heo, Y Lim, W Lee, SH Cho, J Ahn… - British journal of …, 2023 - nature.com
Background Postoperative minimal residual disease (MRD) detection using circulating-
tumour DNA (ctDNA) requires a highly sensitive analysis platform. We have developed a …
tumour DNA (ctDNA) requires a highly sensitive analysis platform. We have developed a …
Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)
Current evaluation of treatment response in solid tumors depends on dynamic changes in
tumor diameters as measured by imaging. However, these changes can only be detected …
tumor diameters as measured by imaging. However, these changes can only be detected …
[HTML][HTML] Genetics of hepatocellular carcinoma: from tumor to circulating DNA
C Campani, J Zucman-Rossi, JC Nault - Cancers, 2023 - mdpi.com
Simple Summary In recent years, the genetic landscape of hepatocellular carcinoma (HCC)
has been explored, identifying TERT promoter, CTNNB1, and TP53 as the most frequent …
has been explored, identifying TERT promoter, CTNNB1, and TP53 as the most frequent …
[HTML][HTML] Circulating tumour DNA as biomarker for colorectal liver metastases: a systematic review and meta-analysis
L Wullaert, JM van Rees, JWM Martens, HMW Verheul… - Cells, 2023 - mdpi.com
Circulating tumour DNA (ctDNA) is a potential biomarker that could contribute to more
judicious patient selection for personalised treatment. This review and meta-analysis gives …
judicious patient selection for personalised treatment. This review and meta-analysis gives …
[HTML][HTML] Circulating histones to detect and monitor the progression of cancer
Liquid biopsies have emerged as a minimally invasive cancer detection and monitoring
method, which could identify cancer-related alterations in nucleosome or histone levels and …
method, which could identify cancer-related alterations in nucleosome or histone levels and …
[HTML][HTML] Circular and circulating DNA in inflammatory bowel disease: from pathogenesis to potential molecular therapies
F Di Vincenzo, Y Yadid, V Petito, V Emoli, L Masi… - Cells, 2023 - mdpi.com
Inflammatory bowel diseases (IBD), including Crohn's Disease (CD) and Ulcerative Colitis
(UC) are chronic multifactorial disorders which affect the gastrointestinal tract with variable …
(UC) are chronic multifactorial disorders which affect the gastrointestinal tract with variable …
[HTML][HTML] Accelerating the development and validation of liquid biopsy for early cancer screening and treatment tailoring
Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-
derived components in body fluids. It provides an alternative to current cancer screening …
derived components in body fluids. It provides an alternative to current cancer screening …
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …
Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
F Wang, S Lu, D Cao, J Qian, C Li, R Zhang… - …, 2023 - Taylor & Francis
This study aimed to validate the prognostic value of Immunoscore (IS) in stage II colorectal
cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant …
cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant …
New developments in targeted therapy for metastatic colorectal cancer
Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of
metastatic CRC (mCRC) remains poor. Recent advancements in translational research have …
metastatic CRC (mCRC) remains poor. Recent advancements in translational research have …